Hyperfine (NASDAQ:HYPR – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at B. Riley Financial in a report released on Wednesday, Benzinga reports. They currently have a $1.40 price objective on the stock, down from their prior price objective of $1.60. B. Riley Financial‘s price target indicates a potential upside of 132.95% from the stock’s previous close.
A number of other research analysts have also recently issued reports on the stock. Lucid Cap Mkts initiated coverage on shares of Hyperfine in a report on Tuesday, October 27th. They set a “strong-buy” rating for the company. Loop Capital set a $2.00 target price on shares of Hyperfine in a research note on Tuesday, October 27th. Wall Street Zen raised shares of Hyperfine from a “sell” rating to a “hold” rating in a research report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperfine in a report on Thursday, October 15th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Hyperfine in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1.98.
Get Our Latest Analysis on HYPR
Hyperfine Stock Down 1.5%
Hyperfine stock traded down $0.01 during midday trading on Wednesday, hitting $0.60. 21,231 shares of the company were exchanged, compared to its average volume of 728,448. Hyperfine has a fifty-two week low of $0.54 and a fifty-two week high of $1.94. The company has a market cap of $63.83 million, a PE ratio of -1.98 and a beta of 1.49. The company has a debt-to-equity ratio of 0.42, a current ratio of 5.10 and a quick ratio of 4.50. The company’s fifty day moving average price is $0.77 and its 200-day moving average price is $1.09.
Hyperfine (NASDAQ:HYPR – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Hyperfine had a negative return on equity of 91.18% and a negative net margin of 156.42%. The business had revenue of $5.96 million during the quarter, compared to the consensus estimate of $5.84 million. On average, research analysts predict that Hyperfine will post -0.34 EPS for the current fiscal year.
Hedge Funds Weigh In On Hyperfine
Hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in Hyperfine by 165.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 90,917 shares of the company’s stock valued at $73,000 after buying an additional 56,689 shares during the period. Empowered Funds LLC acquired a new position in Hyperfine in the third quarter worth approximately $78,000. Global Retirement Partners LLC raised its holdings in Hyperfine by 371.6% during the third quarter. Global Retirement Partners LLC now owns 40,084 shares of the company’s stock valued at $32,000 after buying an additional 31,584 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Hyperfine by 7,695.4% in the third quarter. Russell Investments Group Ltd. now owns 487,994 shares of the company’s stock worth $394,000 after purchasing an additional 481,734 shares during the period. Finally, PFS Partners LLC increased its holdings in shares of Hyperfine by 150.0% during the 3rd quarter. PFS Partners LLC now owns 50,000 shares of the company’s stock worth $40,000 after purchasing an additional 30,000 shares during the period. Institutional investors and hedge funds own 15.03% of the company’s stock.
About Hyperfine
Hyperfine, Inc. develops portable magnetic resonance imaging (MRI) technology for brain imaging. Its Swoop system is a low-field MRI scanner designed to bring imaging to patients at the point of care, including settings where access to conventional MRI equipment may be limited. The Swoop system is designed for use near a patient’s bedside and does not require a dedicated MRI suite. The U.S. Food and Drug Administration cleared the system in 2020, marking a milestone for the use of portable MRI in clinical care.
Further Reading
- Five stocks we like better than Hyperfine
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Hyperfine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperfine and related companies with MarketBeat.com's FREE daily email newsletter.
